Products
Imvotamab Biosimilar Bispecific IgM Antibody (CD3 × CD20) for Research
Cat No.: GMP-Bios-INN-1233
Anti-CD3E therapeutic antibody (Pre-made Imvotamab biosimilar,Pentameric IgM with Fused scFv (Bispecific)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Imvotamab (development code IGM-2323) is a bispecific pentameric IgM antibody targeting CD20 (MS4A1). It is developed by IGM Biosciences for non-Hodgkin lymphoma and other B-cell malignancies. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1233-1mg | 1mg | |
| GMP-Bios-INN-1233-10mg | 10mg | |
| GMP-Bios-INN-1233-100mg | 100mg | |
| GMP-Bios-INN-1233-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Imvotamab biosimilar, Pentameric IgM with Fused scFv (Bispecific), Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Imvotamab |
| Target | CD3E;MS4A1/CD20 |
| Format | Pentameric IgM with Fused scFv (Bispecific) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | M |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | IGM Biosciences |
| Conditions Approved | na |
| Conditions Active | Non-Hodgkin's lymphoma; Diffuse Large B cell lymphoma; Follicular lymphoma;Mantle cell lymphoma;Splenic marginal zone lymphoma; |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
